Edition:
United States

Biocept Inc (BIOC.OQ)

BIOC.OQ on NASDAQ Stock Exchange Capital Market

2.92USD
24 Sep 2018
Change (% chg)

$-0.02 (-0.68%)
Prev Close
$2.94
Open
$3.02
Day's High
$3.02
Day's Low
$2.87
Volume
44,753
Avg. Vol
86,104
52-wk High
$40.20
52-wk Low
$2.87

Chart for

About

Biocept, Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company's Target-Selector offering is based on an internally... (more)

Overall

Beta: 1.59
Market Cap(Mil.): $6.68
Shares Outstanding(Mil.): 2.27
Dividend: --
Yield (%): --

Financials

  BIOC.OQ Industry Sector
P/E (TTM): -- 39.51 32.69
EPS (TTM): -14.40 -- --
ROI: -336.91 14.13 12.72
ROE: -433.16 17.35 14.85

BRIEF-Biocept Inc Files For Mixed Shelf Of Up To $50 Million

* BIOCEPT INC FILES FOR MIXED SHELF OF UP TO $50 MILLION – SEC FILING Source http://bit.ly/2wJv6pr Further company coverage:

May 15 2018

BRIEF-Biocept Q1 Loss Per Share $0.11

* Q1 REVENUE $800,000 VERSUS $1.7 MILLION Source text for Eikon: Further company coverage:

May 15 2018

BRIEF-Biocept Inc Obtains Patent For A Certain Technology In China

* BIOCEPT OBTAINS PATENT FOR ITS TARGET SELECTOR MOLECULAR BIOMARKER TECHNOLOGY IN CHINA Source text for Eikon: Further company coverage:

Mar 29 2018

BRIEF-Biocept Reports Q4 Loss Of $0.18 Per Share

* BIOCEPT REPORTS 2017 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS

Mar 28 2018

BRIEF-Biocept And Thermo Fisher Scientific Enter Into Technology And Commercial Collaboration

* BIOCEPT AND THERMO FISHER SCIENTIFIC ENTER INTO TECHNOLOGY AND COMMERCIAL COLLABORATION

Mar 28 2018

Earnings vs. Estimates